### Meningococcal Vaccines—High-risk Populations

<table>
<thead>
<tr>
<th>Risk groups:</th>
<th>Exp. Increased Exposure to meningococcal serogroups covered by vaccines (due to outbreaks¹, travel to affected areas [e.g. the Hajj], lab exposure)</th>
<th>CD. Persistent Complement component Deficiencies (including persons taking complement inhibitor [e.g., eculizumab® or ravulizumab®])</th>
<th>Asp. Functional or Anatomic Asplenia (including sickle cell disease)</th>
<th>HIV. HIV Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at first dose</td>
<td>Exp</td>
<td>CD</td>
<td>Asp</td>
<td>HIV</td>
</tr>
</tbody>
</table>

#### 2–6 months ⁴
- Exp: ✓ ✓ ✓ ✓
- CD: ✓ ✓ ✓ ✓
- Asp: ✓ ✓ ✓ ✓
- HIV: ✓ ✓ ✓ ✓
- 2 months: ACWY-CRM
  - Menveo®
- 4 months: ACWY-CRM
  - Menveo®
- 6 months: ACWY-CRM
  - Menveo®
- 12–15 months: ACWY-CRM
  - Menveo®

#### 7–23 months
- Exp: ✓ ✓ ✓ ✓
- CD: ✓ ✓ ✓ ✓
- Asp: ✓ ✓ ✓ ✓
- HIV: ✓ ✓ ✓ ✓
- 3 months: ACWY-CRM
  - Menveo®
- 2 months: ACWY-CRM
  - Menveo®

#### 2 years and older
- Exp: ✓ ✓ ✓ ✓
- CD: ✓ ✓ ✓ ✓
- Asp: ✓ ✓ ✓ ✓
- HIV: ✓ ✓ ✓ ✓
- 2 months: ACWY-CRM
  - Menveo® or MenQuad/f_i®

#### 2) Also give MenB vaccine—may be given at same time as MenACWY vaccine. Use the same brand for each dose in the series.

#### 10 years and older
- Exp: ✓ ✓ ✓ ✓
- CD: ✓ ✓ ✓ ✓
- Asp: ✓ ✓ ✓ ✓
- HIV: ✓ ✓ ✓ ✓

#### 1st dose:
- MenB-4C
  - Bexsero®
- MenB-FHbp
  - Trumenba®

#### 2nd dose:
- MenB-4C
  - Bexsero®
- MenB-FHbp
  - Trumenba®

#### 3rd dose:
- MenB-FHbp
  - Trumenba®

**Boosters**

- Lab exposure, complement deficiency, asplenia:
  - Exp: ✓ ✓ ✓ ✓
  - CD: ✓ ✓ ✓ ✓
  - Asp: ✓ ✓ ✓ ✓
  - Lab: 1 year
  - MenB: Every 2–3 years
  - MenB: MenB

- Increased risk during an outbreak:
  - Outbreak: 1+ years
  - MenB: MenB

---

For further details, see [www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html](http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html). For routine use, see [EZIZ.org/assets/docs/IMM-1217.pdf](http://EZIZ.org/assets/docs/IMM-1217.pdf).

1. Information on outbreaks at [https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/meningococcal.aspx](https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/meningococcal.aspx)
2. Abbreviations: ACWY/ACWY-CRM/ACWY-TT = MenACWY = MCV4
3. If no longer at high risk by age 10, administer additional two doses of MenACWY according to the regular adolescent schedule at age 11–12 years and age 16 years.
4. If MenACWY-CRM is initiated at ages 3–6 months, catch-up vaccination includes doses at intervals of 8 weeks until the infant is aged ≥7 months, at which time an additional dose is administered at age ≥7 months, followed by a dose at least 12 weeks later and after the 1st birthday.
5. Minimum age 12 months.

This publication was supported by Grant Number H23/CCH922507 from the Centers for Disease Control and Prevention (CDC)